US · VIVS · BIOTECHNOLOGY
VivoSim Labs, Inc. (VIVS) intrinsic value and stock valuation
$0.26as of 2026-11-21 · Mkt cap 933.7K
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
VivoSim Labs, Inc. DCF and intrinsic value
InvestorsCraft values VIVS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VIVS’s statements →
VivoSim Labs, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- XTL Biopharmaceuticals Ltd. (XTLB) $1.37
- Cyclerion Therapeutics, Inc. (CYCN) $23.52
- Polyrizon Ltd. (PLRZ) $9.31
- Quoin Pharmaceuticals, Ltd. (QNRX) $3.28
- Alaunos Therapeutics, Inc. (TCRT) $1.66
- PharmaCyte Biotech, Inc. (PMCB) $3.98
- Pasithea Therapeutics Corp. (KTTA) $0.48
- Radiopharm Theranostics Limited (RADX) $0.63
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $130K | $140K | $110K | $370K | $1.5M |
| Operating income | -$-11.22M | -$-12.62M | -$-15.09M | -$-17.73M | -$-11.48M |
| Net income | -$-13.84M | -$-2.49M | -$-14.67M | -$-17.26M | -$-11.45M |
| EPSd | -$-5.34M | -$-1.71M | -$-19.3M | -$-23.64M | -$-15.68M |
| Operating cash flow | -$-10.83M | -$-9.46M | -$-14.65M | -$-12.41M | -$-8.45M |
| Capital expenditure | $0.00 | -$-10K | -$-40K | -$-400K | -$-410K |
| Free cash flow | -$-10.83M | -$-9.47M | -$-14.7M | -$-12.8M | -$-8.86M |
| Total assets | $7.39M | $14.7M | $6.35M | $20.3M | $33.3M |
| Total debt | $450K | $940K | $1.39M | $1.8M | $2.18M |
| Net debt | -$-4.58M | -$-10.37M | -$-1.51M | -$-13.5M | -$-26.49M |
| Total equity | -$-1.1M | $10.5M | $3.6M | $15.3M | $30.2M |
| Cash and short-term investments | $5.02M | $11.3M | $2.9M | $16M | $28.7M |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $130K | $140K | $110K | $370K | $1.5M |
| Cost of revenue | $0.00 | $10K | $0.00 | $0.00 | $0.00 |
| Gross profit | $130K | $140K | $110K | $370K | $1.5M |
| Research and development expenses | $4.19M | $5.03M | $5.5M | $8.88M | $3.32M |
| Selling, general and administrative expenses | $7.17M | $7.69M | $9.64M | $9.09M | $9.63M |
| Other expenses | $0.00 | $40K | $50K | $130K | $30K |
| Operating expenses | $11.4M | $12.8M | $15.2M | $18.1M | $13M |
| Cost and expenses | $11.4M | $12.8M | $15.2M | $18.1M | $13M |
| Interest income | $270K | $140K | $410K | $450K | $10K |
| Interest expense | $10K | $10K | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $0.00 | $270K | $280K | $290K | $140K |
| Ebitda | -$-13.57M | -$-2.21M | -$-14.39M | -$-16.96M | -$-11.3M |
| Operating income | -$-11.22M | -$-12.62M | -$-15.09M | -$-17.73M | -$-11.48M |
| Total other income/expenses, net | -$-2.35M | $10.1M | $420K | $470K | $30K |
| Income before tax | -$-13.58M | -$-2.49M | -$-14.67M | -$-17.26M | -$-11.45M |
| Income tax expense | -$0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-13.84M | -$-2.49M | -$-14.67M | -$-17.26M | -$-11.45M |
| Weighted average shares outstanding | $2.59M | $1.46M | $760K | $730K | $730K |
| Weighted average diluted shares outstanding | $2.59M | $1.46M | $760K | $730K | $730K |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.02M | $11.3M | $2.9M | $16M | $28.7M |
| Net receivables | $1.05M | $30K | $30K | $150K | $0.00 |
| Inventory | $0.00 | $0.00 | $300K | $0.00 | $0.00 |
| Total current assets | $6.63M | $12.1M | $3.94M | $17.1M | $29.5M |
| Property, plant and equipment, net | $610K | $1.29M | $1.97M | $2.61M | $2.81M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $760K | $2.52M | $2.41M | $3.27M | $3.76M |
| Total assets | $7.39M | $14.7M | $6.35M | $20.3M | $33.3M |
| Accounts payable | $1.02M | $1.64M | $630K | $330K | $410K |
| Short-term debt | $450K | $520K | $510K | $490K | $480K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $2.79M | $3.74M | $1.86M | $3.67M | $1.38M |
| Long-term debt | $0.00 | $420K | $890K | $1.31M | $1.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $5.7M | $420K | $890K | $1.31M | $1.7M |
| Capital lease obligations | $450K | $940K | $1.39M | $1.8M | $2.18M |
| Total liabilities | $8.48M | $4.16M | $2.75M | $4.98M | $3.09M |
| Common stock | $0.00 | $0.00 | $10K | $10K | $10K |
| Retained earnings | -$-356M | -$-342.16M | -$-339.67M | -$-325M | -$-307.74M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | -$-1.1M | $10.5M | $3.6M | $15.3M | $30.2M |
| Total investments | $0.00 | $0.00 | $0.00 | $710K | $0.00 |
| Total debt | $450K | $940K | $1.39M | $1.8M | $2.18M |
| Net debt | -$-4.58M | -$-10.37M | -$-1.51M | -$-13.5M | -$-26.49M |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | -$-13.84M | -$-2.49M | -$-14.67M | -$-17.26M | -$-11.45M |
| Depreciation and amortization | $210K | $270K | $280K | $290K | $140K |
| Stock-based compensation | $300K | $530K | $1.51M | $2.38M | $2.26M |
| Change in working capital | -$-680K | $1.04M | -$-2.02M | $2.31M | $600K |
| Accounts receivable | -$0.00 | $0.00 | $120K | -$-150K | $0.00 |
| Inventory | $0.00 | -$-500K | -$-300K | $0.00 | $0.00 |
| Accounts payable | -$-620K | $1.02M | $300K | -$-150K | $130K |
| Net cash provided by operating activities | -$-10.83M | -$-9.46M | -$-14.65M | -$-12.41M | -$-8.45M |
| Investments in property, plant and equipment | $0.00 | -$-10K | -$-40K | -$-400K | -$-410K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $90K | $9.03M | $820K | -$-970K | -$-410K |
| Common stock issued | $4.81M | $8.85M | $1.44M | $0.00 | $250K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $4.45M | $8.85M | $1.44M | $0.00 | $200K |
| Net change in cash | -$-6.29M | $8.41M | -$-12.4M | -$-13.37M | -$-8.66M |
| Cash at end of period | $5.17M | $11.5M | $3.04M | $15.4M | $28.8M |
| Operating cash flow | -$-10.83M | -$-9.46M | -$-14.65M | -$-12.41M | -$-8.45M |
| Capital expenditure | $0.00 | -$-10K | -$-40K | -$-400K | -$-410K |
| Free cash flow | -$-10.83M | -$-9.47M | -$-14.7M | -$-12.8M | -$-8.86M |
Line items
Line items
Line items
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- CEO
- Keith Murphy
- Employees
- 15
- Beta
- 1.40
Explore
Frequently asked questions
What is the intrinsic value of VivoSim Labs, Inc. (VIVS)?
InvestorsCraft does not currently publish an intrinsic value for VIVS. How the IC value is calculated.
Is VIVS undervalued?
InvestorsCraft does not publish an undervaluation signal for VIVS at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.